Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $21.14 Consensus Price Target from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have earned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $21.14.

A number of research firms recently commented on YMAB. Truist Financial initiated coverage on shares of Y-mAbs Therapeutics in a research note on Friday, June 28th. They issued a “buy” rating and a $21.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Wedbush restated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. BMO Capital Markets decreased their price objective on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Finally, Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th.

Insider Activity at Y-mAbs Therapeutics

In related news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares in the company, valued at $449,514. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares in the company, valued at $449,514. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Thomas Gad sold 30,000 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the sale, the insider now directly owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 100,000 shares of company stock worth $1,338,100 in the last three months. Company insiders own 21.50% of the company’s stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. increased its holdings in Y-mAbs Therapeutics by 39.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after acquiring an additional 1,056 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Y-mAbs Therapeutics by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,390 shares of the company’s stock worth $136,000 after acquiring an additional 3,340 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Y-mAbs Therapeutics in the 3rd quarter worth $178,000. XTX Topco Ltd purchased a new stake in shares of Y-mAbs Therapeutics during the second quarter worth $297,000. Finally, Caxton Associates LP purchased a new stake in shares of Y-mAbs Therapeutics during the first quarter worth $306,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Up 4.7 %

Shares of Y-mAbs Therapeutics stock opened at $14.16 on Wednesday. The firm’s 50 day moving average price is $13.04 and its 200-day moving average price is $13.24. The company has a market cap of $621.38 million, a P/E ratio of -28.90 and a beta of 0.70. Y-mAbs Therapeutics has a 52-week low of $4.69 and a 52-week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Monday, August 12th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). The company had revenue of $22.80 million during the quarter, compared to analyst estimates of $23.09 million. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. During the same quarter last year, the business earned ($0.14) earnings per share. As a group, equities research analysts forecast that Y-mAbs Therapeutics will post -0.57 EPS for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.